Radioimmunotherapy: A New Treatment Modality for B-Cell Non-Hodgkin’s Lymphoma
نویسندگان
چکیده
We applaud Ghobrial and Witzig for their comprehensive and balanced article on "Radioimmunotherapy: A New Treatment Modality for B-cell NonHodgkin's Lymphoma." These authors have provided a review that will serve the oncologist and oncology patient well. They have not engaged in arcane and tedious discussion of which anti-CD20 monoclonal antibody (ibritumomab tiuxetan [Zevalin] or tositumomab/iodine-131 [I-131] tositumomab [Bexxar]), or radionuclide (yttrium-90 [Y-90] or I-131), or dosing method is better. Wisely, Ghobrial and Witzig have provided accurate distillates of the many publications on these exciting drugs. Because no rigorous body of data clearly indicates that one drug is better than the other, these debates only confuse the oncologist and are better left to the "technocrat."
منابع مشابه
Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملCutaneous lymphomas and pseudolymphomas: A ten-year study at Emam Reza and Omid hospitals in Mashhad, using immunohistochemical and new classification methods
Background: Cutaneous lymphomas are monoclonal neoplastic proliferations of immune cells most frequently T or B cells that infiltrates skin. Development of new diagnostic methods, particularly those for immunophenotyping, have substantially changed classification of these neoplasms. These reasons prompted us to perform this study. Objective: To re-classify cutaneous lymphomas and pseudoly...
متن کاملExtranodal Non-Hodgkin’s Lymphoma of the Oral Cavity Presenting as Gingival Swelling: A Case Report
Non-Hodgkin’s lymphoma is a heterogeneous malignancy originating from proliferation of lymphoid cells or their precursors. , we report a case of a 6-year-old Iranian male child admitted at the Department of Oral Medicine, School of Dentistry, Mashhad, Iran, in March 2019. The case was complaining about gingival swellings worsening for one month. Clinical and pathologic examination, comple...
متن کاملUtilization of Radioimmunotherapy (RIT) and Hematopoietic Stem Cell Transplantation (HSCT) in B-cell Non-Hodgkin’s Lymphoma (NHL): 10 Year Experience of a Single Community Cancer Center
After Yttrium (Y90) Ibritumomab tiuxetan (Zevalin) and Iodine (131I) tositumomab (Bexxar) were approved by the FDA, the improved response of B-cell NHL to this novel RIT makes it a promising alternative to more aggressive treatment like HSCT. In this study, we describe the experience of a single community-based cancer center with RIT and HSCT in patients with B-cell NHL in terms of response, su...
متن کامل